{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:15:38Z","timestamp":1786119338775,"version":"build-2736575974"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.1097\/hco.0b013e328338bc2d","type":"journal-article","created":{"date-parts":[[2010,4,16]],"date-time":"2010-04-16T03:41:00Z","timestamp":1271389260000},"page":"385-393","source":"Crossref","is-referenced-by-count":15,"title":["Lipid-lowering drugs and heart failure: where do we go after the statin trials?"],"prefix":"10.1097","volume":"25","author":[{"given":"Timo E","family":"Strandberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-16-20210204","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1056\/NEJMra021498","article-title":"Heart failure","volume":"348","author":"Jessup","year":"2003","journal-title":"N Engl J Med"},{"key":"R2-16-20210204","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1093\/eurheartj\/ehn309","article-title":"ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008","volume":"29","author":"Dickstein","year":"2008","journal-title":"Eur Heart J"},{"key":"R3-16-20210204","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1161\/CIRCULATIONAHA.107.188965","article-title":"Prevention of heart failure.","volume":"117","year":"2008","journal-title":"Circulation"},{"key":"R4-16-20210204","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"R5-16-20210204","doi-asserted-by":"crossref","first-page":"937","DOI":"10.3949\/ccjm.73.10.937","article-title":"Coronary atherosclerosis can regress with very intensive statin therapy","volume":"73","author":"Sipahi","year":"2006","journal-title":"Cleve Clin J Med"},{"key":"R6-16-20210204","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.ahj.2008.07.004","article-title":"Cholesterol levels and in-hospital mortality in patients with acute decompensated heart failure","volume":"156","author":"Horwich","year":"2008","journal-title":"Am Heart J"},{"key":"R7-16-20210204","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1161\/CIRCHEARTFAILURE.108.825059","article-title":"Reverse epidemiology in systolic and nonsystolic heart failure: cumulative prognostic benefit of classical cardiovascular risk factors","volume":"2","author":"G\u00fcder","year":"2009","journal-title":"Circ Heart Fail"},{"key":"R8-16-20210204","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.amjcard.2009.08.660","article-title":"Baseline low-density lipoprotein cholesterol levels and outcome in patients with heart failure","volume":"105","author":"Charach","year":"2010","journal-title":"Am J Cardiol"},{"key":"R9-16-20210204","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1042\/CS20070031","article-title":"Statins and clinical outcomes in heart failure","volume":"113","author":"Martin","year":"2007","journal-title":"Clin Sci (Lond)"},{"key":"R10-16-20210204","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jacc.2007.10.009","article-title":"Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy","volume":"51","author":"Ramasubbu","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"R12-16-20210204","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.amjmed.2009.01.030","article-title":"Inflammation, coagulation, and the pathway to frailty","volume":"122","author":"Kanapuru","year":"2009","journal-title":"Am J Med"},{"key":"R13-16-20210204","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1007\/s12603-009-0051-8","article-title":"Frailty: defining and measuring of a concept","volume":"13","author":"Pel-Littel","year":"2009","journal-title":"J Nutr Health Aging"},{"key":"R14-16-20210204","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1161\/CIRCULATIONAHA.109.830984","article-title":"Relations of lipid concentrations to heart failure incidence: the Framingham Heart Study","volume":"120","author":"Velagaleti","year":"2009","journal-title":"Circulation"},{"key":"R15-16-20210204","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.amjcard.2005.09.142","article-title":"Usefulness of atorvastatin in patients with heart failure due to inflammatory dilated cardiomyopathy and elevated cholesterol levels","volume":"97","author":"Wojnicz","year":"2006","journal-title":"Am J Cardiol"},{"key":"R16-16-20210204","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/eurheartj\/ehm583","article-title":"The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure","volume":"29","author":"Sever","year":"2008","journal-title":"Eur Heart J"},{"key":"R17-16-20210204","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.jacc.2006.08.052","article-title":"N-terminal Pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC\/BHF heart protection study.","volume":"49","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"R18-16-20210204","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1071-9164(97)90022-1","article-title":"The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease","volume":"3","author":"Kjekshus","year":"1997","journal-title":"J Card Fail"},{"key":"R19-16-20210204","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1016\/S0735-1097(03)01057-X","article-title":"Predictors of late development of heart failure in stable survivors of myocardial infarction. The CARE Study","volume":"42","author":"Lewis","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"R20-16-20210204","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0002-9149(02)02438-4","article-title":"Frequency of congestive heart failure in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol > or = 125 mg\/dl treated with statins versus no lipid-lowering drug","volume":"90","author":"Aronow","year":"2002","journal-title":"Am J Cardiol"},{"key":"R21-16-20210204","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1161\/CIRCULATIONAHA.106.625574","article-title":"Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study","volume":"115","author":"Khush","year":"2007","journal-title":"Circulation"},{"key":"R22-16-20210204","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/j.amjcard.2009.01.377","article-title":"Comparative effect of atorvastatin (80 mg) versus simvastatin (20 to 40 mg) in preventing hospitalizations for heart failure in patients with previous myocardial infarction","volume":"103","author":"Strandberg","year":"2009","journal-title":"Am J Cardiol"},{"key":"R23-16-20210204","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study.","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"R24-16-20210204","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1056\/NEJMoa0706201","article-title":"Rosuvastatin in older patients with systolic heart failure","volume":"357","author":"Kjekshus","year":"2007","journal-title":"N Engl J Med"},{"key":"R25-16-20210204","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0140-6736(08)61240-4","article-title":"Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial.","volume":"372","year":"2008","journal-title":"Lancet"},{"key":"R26-16-20210204","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1016\/j.jacc.2006.03.034","article-title":"Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study","volume":"47","author":"Scirica","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"R27-16-20210204","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jama.292.11.1307","article-title":"Early intensive vs. a delayed conservative simvastatin therapy in patients with acute coronary syndromes: phase Z of A to Z trial","volume":"292","author":"de Lemos","year":"2004","journal-title":"J Am Med Assoc"},{"key":"R28-16-20210204","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/eurjhf\/hfn046","article-title":"Predictors of fatal and nonfatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide","volume":"11","author":"Wedel","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"R29-16-20210204","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1016\/j.jacc.2009.06.041","article-title":"Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure)","volume":"54","author":"Cleland","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"R30-16-20210204","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1093\/eurjhf\/hfp172","article-title":"An economic evaluation of rosuvastatin treatment in systolic heart failure: evidence from the CORONA trial","volume":"12","author":"Lorgelly","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"R31-16-20210204","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/S0140-6736(08)61239-8","article-title":"Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial.","volume":"372","year":"2008","journal-title":"Lancet"},{"key":"R32-16-20210204","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/0003319707313882","article-title":"CORONA, statins, and heart failure: who lost the crown?","volume":"59","author":"Athyros","year":"2008","journal-title":"Angiology"},{"key":"R33-16-20210204","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1371\/journal.pmed.0030333","article-title":"Statins in the treatment of chronic heart failure: a systematic review","volume":"3","author":"van der Harst","year":"2006","journal-title":"PLoS Med"},{"key":"R34-16-20210204","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1001\/jama.296.17.2105","article-title":"Statin therapy and risks of death and hospitalization in chronic heart failure","volume":"296","author":"Go","year":"2006","journal-title":"J Am Med Assoc"},{"key":"R37-16-20210204","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.jacc.2008.08.081","article-title":"Insulin resistance is highly prevalent and is associated with reduced exercise tolerance in nondiabetic patients with heart failure","volume":"53","author":"AlZadjali","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"R38-16-20210204","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol","volume":"341","author":"Rubins","year":"1999","journal-title":"N Engl J Med"},{"key":"R39-16-20210204","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/07853890802609534","article-title":"Is high HDL cholesterol always good?","volume":"41","author":"Olsson","year":"2009","journal-title":"Ann Med"},{"key":"R40-16-20210204","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/HCO.0b013e32832ebfe7","article-title":"Enhancing cardiovascular disease risk reduction: raising high-density lipoprotein levels","volume":"24","author":"Hausenloy","year":"2009","journal-title":"Curr Opin Cardiol"},{"key":"R41-16-20210204","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa0907569","article-title":"Extended-release niacin or ezetimibe and carotid intima-media thickness","volume":"361","author":"Taylor","year":"2009","journal-title":"N Engl J Med"},{"key":"R42-16-20210204","doi-asserted-by":"crossref","first-page":"865","DOI":"10.3109\/00365510903359237","article-title":"High-density lipoprotein is superior to B-type natriuretic peptide as a marker of systolic dysfunction in an elderly general population","volume":"69","author":"Kerola","year":"2009","journal-title":"Scand J Clin Lab Invest"},{"key":"R43-16-20210204","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.healun.2009.04.026","article-title":"High-density lipoprotein cholesterol levels and prognosis in advanced heart failure","volume":"28","author":"Mehra","year":"2009","journal-title":"J Heart Lung Transplant"},{"key":"R44-16-20210204","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.atherosclerosis.2009.01.023","article-title":"Congestive heart failure is associated with lipoprotein components in statin-treated patients with coronary heart disease Insights from the Incremental Decrease in End points Through Aggressive Lipid Lowering Trial (IDEAL)","volume":"205","author":"Holme","year":"2009","journal-title":"Atherosclerosis"}],"container-title":["Current Opinion in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/HCO.0b013e328338bc2d","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:18:48Z","timestamp":1786040328000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001573-201007000-00016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/hco.0b013e328338bc2d","relation":{},"ISSN":["0268-4705"],"issn-type":[{"value":"0268-4705","type":"print"}],"subject":[],"published":{"date-parts":[[2010,7]]}}}